Glucose Consumption During Deep Brain Stimulation With Functional [18F]FDG-Brain-PET in Obsessive-Compulsive Disorder
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Implantation of a DBS therapy system.
- Who it may be relevant to
- Registry conditions: Obsessive-Compulsive Disorder, Psychiatric Disorder. Basic parameters: 18 years — 75 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Austria
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
The purpose of this randomized, sham-controlled study is to evaluate the effectiveness of DBS therapy in individuals suffering from severe OCD and to investigate DBS treatment with functional \[18F\]FDG-Brain-PET.
Detailed description
The overall planned study duration per subject is 36 weeks, whereby inclusion is timepoint zero and implantation of DBS will be conducted during the first four study weeks. Patients will then undergo an 8-week open-label active DBS treatment phase followed by a 12-week double blind active or sham treatment and finally a 12-week crossover period with the inverse (active/sham) treatment with at least biweekly study visits. Patients as well as patient handling study psychiatrists will be blinded to active/sham. In case of unbearable aggravation of the symptoms during sham, the sham-period will be shortened to a tolerable length. After maximal 38 weeks all study procedures will be completed, and active DBS treatment will be maintained as long as clinically necessary.
Interventions
- Device Implantation of a DBS therapy system
The system is called "Reclaim DBS Therapy for OCD" und is marketed by Medtronic (Minneapolis, Minnesota). It has a HDE status by the FDA. The system consists of two quadripolar electrodes (Medtronic Reclaim DBS) as well as a generator (Medtronic Activa PC), which will be implanted into a subcutaneous pocket below the clavicula.
Primary outcome measures
- Change of metabolic rates of glucose response pattern [Time frame: fPET measurements will take place in Week 4 and Week 5 of the trial.]
Secondary outcome measures (3)
- Determination of association between metabolic (change in glucose consumption - PET), structural (white matter pathways - DTI) and functional connectivity (resting state fMRI - functional connectivity patterns) [Time frame: Data acquisition will take place during screening and in the first 5 weeks of the study.]
- Change in YBOCS scores by active DBS treatment and sham treatment [Time frame: Week 1 to 38]
- Correlation of metabolic (change in glucose consumption) and connectivity measures (white matter pathways) with clinical outcomes (YBOCS) and neuropsychological tests (SSRT, n-back, WCST) [Time frame: Data acquisition will take place during screening and in Week 1 to Week 38 of the study.]
Eligibility criteria
Inclusion criteria
- a score of 25 or higher on the Yale-Brown Obsessive Compulsive Scale
- previous failure to respond to at least two medication trials with serotonin reuptake inhibitors at or, if tolerated, beyond the FDA maximum recommended dose for a minimum duration over at least ten weeks each.
- at least one trial with tricyclic medication at or, if tolerated, beyond the FDA maximum recommended dose for a minimum duration over at least ten weeks each.
- at least one trial of augmentation with antipsychotic medication, lithium, a benzodiazepine or buspirone
- at least on trial of psychotherapy (cognitive behavioral therapy or comparable techniques) for at least 20 sessions
- ability to provide written informed consent
Exclusion criteria
- any history of current or past psychotic disorder
- a manic episode within the preceding three years
- any current clinically significant medical or neurological disorder, that is a contraindication against DBS
- any disease that could lead to an altered glucose reactivity (e.g. diabetes)
- any clinically significant preoperative MRI abnormality or inability to undergo presurgical MRI
- current or unstable remitted substance abuse or dependence except nicotine
- pregnancy or high risk of becoming pregnant during study duration (desire to have children) and refusal to utilize a proper method of contraception
- Any current severe personality disorder except comorbid anankastic personality disorder
- Inability to follow the study protocol or adhere to operational requirements
- Current and unstable suicidality
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Triple blind
- Primary purpose
- Treatment
Study locations
Austria · 1 center
- Medical University of Vienna, Department of Psychiatry and Psychotherapy — Vienna
Identifiers
NCT: NCT05577598 · V4 03062020